The company’s path to potential approval remains complex following a Complete Response Letter issued last June. The FDA categorized this latest filing as a Class II submission, triggering a standard six-month review window. While the March 2027 date serves as the current regulatory anchor, Unicycive is exploring avenues to accelerate that timeline.
In section Market Quotes
Unicycive Therapeutics Gains Momentum Following FDA Resubmission
Shares of Unicycive Therapeutics climbed 5% to $4 in morning trading after the company announced the FDA accepted its resubmitted application for oxylanthanum carbonate. The agency set a target action date of March 25, 2027, for the oral phosphate binder intended to treat hyperphosphatemia in dialysis patients.
Management is currently navigating uncertainty regarding third-party manufacturing inspections. The firm remains in limbo over whether the FDA will mandate a pre-approval audit of its new product vendor. Should the original manufacturing partner successfully demonstrate compliance with current Good Manufacturing Practices during an upcoming inspection, Unicycive intends to petition the agency for an expedited path to market. Ultimately, the timing of any facility oversight rests entirely with federal regulators.
Comments (0)
No comments yet. Be the first!